Anti–GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)

<strong>Objectives </strong>To investigate the efficacy and safety of otilimab, an anti-granulocyte-macrophage colony-stimulating factor antibody, in patients with active rheumatoid arthritis and an inadequate response to conventional synthetic (cs) and biologic disease-modifying antirhe...

Full description

Bibliographic Details
Main Authors:	Taylor, PC, Weinblatt, M, McInnes, IB, Atsumi, T, Strand, V, Takeuchi, T, Bracher, M, Brooks, D, Davies, J, Goode, C, Gupta, A, Mukherjee, S, O’Shea, C, Saurigny, D, Schifano, L, Shelton, C, Smith, JE, Wang, M, Wang, R, Watts, S, Fleischmann, R
Format:	Journal article
Language:	English
Published:	BMJ Publishing Group 2023

Anti–GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)

Similar Items